is highly speculative but he thinks the risk-reward makes it worth a try.
Cramer said he's still bullish on
is still far too hard to understand or opine on.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer followed up on his interview last night with the CEO of
Charles River Laboratories
. He said any company working on conquering disease needs basic research, and Charles River is clearly the leader in that space. But isn't it odd Big Pharma is winding down its research spending at the same time biotechs are adding to theirs?
Cramer said this trend shows how old-line Big Pharma is ceding its leadership to the next generation of small biotech firms that are just as hungry as they were in the 1990s. Biotechs are risk takers, he said, while Big Pharma has now relegated itself to merely buying back stock to help boost earnings per share.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,